Trans Genic Inc.

2342

JP3635720000

Department Stores

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-02 am EDT			5-day change	1st Jan Change
233 ^JPY	0.00%		-11.41%	-10.38%

Jan. 24	Tranche Update on Trans Genic Inc.'s Equity Buyback Plan announced on November 22, 2023.	CI
Jan. 23	Trans Genic Inc.'s Equity Buyback announced on November 22, 2023, has closed with 300,000 shares, representing 1.78% for ¥78.62 million.	CI

Eurofins Clinical Testing Lux Holding Sarl entered into a share purchase agreement to acquire GeneticLab Co., Ltd. from Trans Genic Inc. for ¥3.2 billion.

December 09, 2021

Eurofins Clinical Testing Lux Holding Sarl entered into a share purchase agreement to acquire GeneticLab Co., Ltd. from Trans Genic Inc. (TSE:2342) for ¥3.2 billion on December 10, 2021. The transaction is for 82328 shares. As of March 31, 2021, GeneticLab Co., Ltd. had net assets of ¥53 million and total assets of ¥1856 million.

For the year ending December 31, 2021, GeneticLab Co., Ltd. reported sales of ¥1697 million, EBIT of ¥760 million, Net income of ¥608 million.

Latest news about Trans Genic Inc.

Tranche Update on Trans Genic Inc.'s Equity Buyback Plan announced on November 22, 2023.	Jan. 24	CI
Trans Genic Inc.'s Equity Buyback announced on November 22, 2023, has closed with 300,000 shares, representing 1.78% for ¥78.62 million.	Jan. 22	CI
Tranche Update on Trans Genic Inc.'s Equity Buyback Plan announced on November 22, 2023.	Jan. 04	CI
Trans Genic Inc. announces an Equity Buyback for 300,000 shares, representing 1.78% for ¥100 million.	Nov. 22	CI
Trans Genic Inc. authorizes a Buyback Plan.	Nov. 21	CI
Trans Genic Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-12	CI
Trans Genic Inc. acquired MASC Co., Ltd.	23-03-15	CI
Eurofins Clinical Testing Lux Holding Sarl entered into a share purchase agreement to acquire GeneticLab Co., Ltd. from Trans Genic Inc. for ¥3.2 billion.	21-12-09	CI
Tranche Update on Trans Genic Inc.'s Equity Buyback Plan announced on August 25, 2021.	21-11-23	CI
Trans Genic Inc.'s Equity Buyback announced on August 25, 2021, has closed with 550,000 shares, representing 3.19% for ¥298.6 million.	21-11-21	CI
Trans Genic Inc. completed the acquisition of Lunapas LLC.	21-10-31	CI
Tranche Update on Trans Genic Inc.'s Equity Buyback Plan announced on August 25, 2021.	21-10-01	CI
Trans Genic Inc. entered into share transfer agreement to acquire Lunapas LLC.	21-09-06	CI
Trans Genic Inc. announces an Equity Buyback for 550,000 shares, representing 3.17% for ¥300 million.	21-08-25	CI
Trans Genic Inc. authorizes a Buyback Plan.	21-08-24	CI
Japan's Nikkei dips on investor caution, Topix buoyed by BOJ talk	19-01-17	RE
Medicinal Chemistry Pharmaceuticals,Co.,Ltd. announced that it has received ¥0.08 million in funding from Trans Genic Inc.	18-04-01	CI
Medicinal Chemistry Pharmaceuticals,Co.,Ltd. announced that it expects to receive ¥0.08 million in funding from Trans Genic Inc.	18-03-18	CI
Trans Genic Inc. announced that it has received ¥17.45 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	17-10-26	CI
Trans Genic Inc. announced that it expects to receive ¥17.45 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm	17-10-10	CI
Kikuyo Sakaguchi cancelled the acquisition of remaining 30% stake in Immunokick Inc. from Trans Genic Inc..	17-07-21	CI
Transgenic Inc. Enters into Joint Research Agreement with Immuno-Biological Laboratories Co. Ltd	17-06-27	CI
Kikuyo Sakaguchi agreed to acquire remaining 30% stake in Immunokick Inc. from Trans Genic Inc. for ¥3 million.	16-07-21	CI
CURED Co., Ltd. announced that it has received ¥159.6 million in funding from Trans Genic Inc., Immuno-Biological Laboratories Co., Ltd.	16-05-10	CI
CURED announced that it expects to receive ¥159.6 million in funding from Trans Genic Inc. and Immuno-Biological Laboratories Co., Ltd.	16-04-19	CI

Chart Trans Genic Inc.

Duration

Period

More charts

Company Profile

TRANS GENIC INC. is a Japan-based company mainly engaged in the biotechnology business. The Company has three business segments. The Contract Research Organization (CRO) segment is engaged in the provision of contract clinical tests for pharmaceuticals and foods, pharmacodynamic pharmacology tests, safety pharmacology tests, pharmacokinetic tests, and non-clinical tests such as safety tests for pesticides and food, the contract production of genetically modified mice and antibody, the sale of model mice, as well as the development of new biomarkers. The Diagnostic Analysis segment is engaged in the provision of pathological diagnosis services, gene analysis contract services, and drug discovery support services for individualized medicine. The TGBS segment is engaged in the provision of advice and support services for business succession and revitalization in various fields, as well as the electronic commerce (EC) business such as the retail and wholesale of electrical products.

Sector

Department Stores

Calendar

2024-05-09 - Q4 2023 Earnings Release

More about the company

	1st Jan change	Capi.
TRANS GENIC INC.	-10.38%	25.18M
AMAZON.COM, INC.	+22.76%	1,922B
JD.COM, INC.	+13.33%	49.95B
COUPANG, INC.	+41.85%	40.21B
ALLEGRO.EU S.A.	+2.63%	8.91B
WAYFAIR INC.	+1.62%	7.06B
ETSY, INC.	-25.95%	6.95B
ZOZO, INC.	+5.70%	6.48B
FSN E-COMMERCE VENTURES LIMITED	-0.14%	6.05B
MONOTARO CO., LTD.	+19.03%	5.92B

Internet & Mail Order Department Stores

Trans Genic Inc.

Equities

2342

JP3635720000

Department Stores

Eurofins Clinical Testing Lux Holding Sarl entered into a share purchase agreement to acquire GeneticLab Co., Ltd. from Trans Genic Inc. for ¥3.2 billion.

Latest news about Trans Genic Inc.

Chart Trans Genic Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Internet & Mail Order Department Stores